13F Holdings
中文EN

CPMV Mosaic ImmunoEngineering Inc.

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 836564 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY0.8%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-2,254.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets238,930.6%
Debt / equity—
Current ratio0.00x
Interest coverage-60.40x

Cash quality & payout

Operating cash flow / net income0.08x
Accruals ratio-2,078.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$63,981$183,867$435,449$1.05M$1.46M
SG&A expense$552,138$695,788$964,319$1.58M$2.05M
Operating income-$616,119-$879,655-$1.40M-$2.63M-$3.50M
Interest expense$10,001$6,954$0——
Pretax income-$685,446-$919,583-$1.01M-$2.38M-$3.68M
Income tax$2,400$2,400$2,400$2,400$2,400
Net income-$687,846-$921,983-$1.01M-$2.38M-$3.68M
EPS (basic)-0.10-0.13-0.14-0.33-0.55
EPS (diluted)-0.10-0.13-0.14-0.33-0.55
Weighted avg. shares (diluted)—7.24M7.24M7.24M6.71M
Banking
Noninterest expense——$73,333$69,738$30,121
Balance sheet
Cash & equivalents$3,622$115,019$156,178$220,645$226,142
Current assets$19,882$141,611$179,533$261,277$269,494
Total assets$19,882$141,611$179,533$261,277$269,494
Current liabilities$6.03M$5.54M$4.73M$3.92M$2.33M
Total liabilities$7.50M$6.93M$6.05M$5.15M$3.07M
Shareholders' equity-$7.48M-$6.79M-$5.87M-$4.88M-$2.80M
Shares outstanding7.24M7.24M7.24M7.24M7.24M
Cash flow statement
Operating cash flow-$111,397-$241,159-$497,467-$690,129-$679,236
Investing cash flow—$0$433,000$343,000$27,637
Financing cash flow$0$200,000$0$341,632$525,003
Stock-based compensation$0$4,867$21,935$295,123$1.31M

Free plan shows the latest 5 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.